Understanding cytokine and growth factor receptor activation mechanisms

Our understanding of the detailed mechanism of action of cytokine and growth factor receptors – and particularly our quantitative understanding of the link between structure, mechanism and function – lags significantly behind our knowledge of comparable functional protein classes such as enzymes, G protein-coupled receptors, and ion channels. In particular, it remains controversial whether such receptors are activated by a mechanism of ligand-induced oligomerization, versus a mechanism in which the ligand binds to a pre-associated receptor dimer or oligomer that becomes activated through subsequent conformational rearrangement. A major limitation to progress has been the relative paucity of methods for performing quantitative mechanistic experiments on unmodified receptors expressed at endogenous levels on live cells. In this article, we review the current state of knowledge on the activation mechanisms of cytokine and growth factor receptors, critically evaluate the evidence for and against the different proposed mechanisms, and highlight other key questions that remain unanswered. New approaches and techniques have led to rapid recent progress in this area, and the field is poised for major advances in the coming years which promise to revolutionize our understanding of this large and biologically and medically important class of receptors.

[1]  D. Haylock,et al.  Principal signalling complexes in haematopoiesis: structural aspects and mimetic discovery. , 2011, Cytokine & growth factor reviews.

[2]  Michael L Doyle,et al.  Selective Binding and Oligomerization of the Murine Granulocyte Colony-stimulating Factor Receptor by a Low Molecular Weight, Nonpeptidyl Ligand* , 2003, The Journal of Biological Chemistry.

[3]  S. Bass,et al.  Zinc mediation of the binding of human growth hormone to the human prolactin receptor. , 1990, Science.

[4]  Quincy Teng,et al.  Structural Biology , 2013, Springer US.

[5]  S. Constantinescu,et al.  Structural Requirements of the Extracellular to Transmembrane Domain Junction for Erythropoietin Receptor Function* , 2005, Journal of Biological Chemistry.

[6]  P. Heinrich,et al.  The membrane distal half of gp130 is responsible for the formation of a ternary complex with IL‐6 and the IL‐6 receptor , 1995, FEBS letters.

[7]  D. Harrison,et al.  The JAK/STAT signaling pathway , 2004, Journal of Cell Science.

[8]  B. Posner,et al.  Cellular signalling: Peptide hormones and growth factors. , 2010, Progress in brain research.

[9]  D. Lauffenburger,et al.  Interleukin 2 (IL-2) variants engineered for increased IL-2 receptor alpha-subunit affinity exhibit increased potency arising from a cell surface ligand reservoir effect. , 2004, Molecular pharmacology.

[10]  M. Emgenbroich,et al.  Erythropoietin mimetic compound AGEM400(HES) binds to the same receptor as erythropoietin but displays a different spectrum of activities. , 2012, Cytokine.

[11]  J G Gleason,et al.  A small, nonpeptidyl mimic of granulocyte-colony-stimulating factor [see commetns]. , 1998, Science.

[12]  Robert M Stroud,et al.  Mechanistic Diversity of Cytokine Receptor Signaling Across Cell Membranes , 2004, Science's STKE.

[13]  Hisashi Q. Higuchi On the nature of , 1999 .

[14]  Huawei Qiu,et al.  Homodimerization Restores Biological Activity to an Inactive Erythropoietin Mutant* , 1998, The Journal of Biological Chemistry.

[15]  C. Heldin,et al.  Dimerization of cell surface receptors in signal transduction , 1995, Cell.

[16]  A. Wilks,et al.  Identification of JAK protein tyrosine kinases as signaling molecules for prolactin. Functional analysis of prolactin receptor and prolactin‐erythropoietin receptor chimera expressed in lymphoid cells. , 1994, The EMBO journal.

[17]  A. Whitty,et al.  Quantitative analysis of the activation mechanism of the multicomponent growth-factor receptor Ret , 2006, Nature chemical biology.

[18]  J. Louis,et al.  GDNF–Induced Activation of the Ret Protein Tyrosine Kinase Is Mediated by GDNFR-α, a Novel Receptor for GDNF , 1996, Cell.

[19]  D. Chang,et al.  Activation of the Erythropoietin (EPO) Receptor by Bivalent Anti-EPO Receptor Antibodies* , 1996, The Journal of Biological Chemistry.

[20]  K. Rose,et al.  Characterization of new multimeric erythropoietin receptor agonists , 2008, Biopolymers.

[21]  L. D. Ward,et al.  High affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor, and gp-130. , 1994, The Journal of biological chemistry.

[22]  S. Skaper Peptide mimetics of neurotrophins and their receptors. , 2011, Current pharmaceutical design.

[23]  Yu-Chin Li,et al.  Bivalent peptidomimetic ligands of TrkC are biased agonists and selectively induce neuritogenesis or potentiate neurotrophin-3 trophic signals. , 2009, ACS chemical biology.

[24]  P. Gregersen,et al.  Structural biology of shared cytokine receptors. , 2009, Annual review of immunology.

[25]  Wen He,et al.  An antagonist peptide–EPO receptor complex suggests that receptor dimerization is not sufficient for activation , 1998, Nature Structural Biology.

[26]  I. Maruyama,et al.  All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells , 2008, Journal of Cell Science.

[27]  H. Holtmann,et al.  Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. , 1990, The Journal of biological chemistry.

[28]  P. Hass,et al.  An agonist murine monoclonal antibody to the human c-Mpl receptor stimulates megakaryocytopoiesis. , 1998, Blood.

[29]  J. Schlessinger Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[30]  D. Lauffenburger,et al.  Affinity regulates spatial range of EGF receptor autocrine ligand binding. , 2002, Developmental biology.

[31]  D. Boger,et al.  Erythropoietin mimetics derived from solution phase combinatorial libraries. , 2002, Journal of the American Chemical Society.

[32]  A. Walker,et al.  Two wrongs can make a right: dimers of prolactin and growth hormone receptor antagonists behave as agonists. , 2006, Molecular endocrinology.

[33]  K Imada,et al.  The Jak-STAT pathway. , 2000, Molecular immunology.

[34]  N. Asai,et al.  Calcium-dependent Ret activation by GDNF and neurturin , 1998, Oncogene.

[35]  A. Citri,et al.  Epigen, the Last Ligand of ErbB Receptors, Reveals Intricate Relationships between Affinity and Mitogenicity* , 2005, Journal of Biological Chemistry.

[36]  D. Stein,et al.  Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death , 2007, Proceedings of the National Academy of Sciences.

[37]  Joseph Schlessinger,et al.  Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.

[38]  T. Pawson,et al.  Assembly of Cell Regulatory Systems Through Protein Interaction Domains , 2003, Science.

[39]  Linda J Pike,et al.  Heterogeneity in EGF-binding affinities arises from negative cooperativity in an aggregating system , 2008, Proceedings of the National Academy of Sciences.

[40]  D. Goeddel,et al.  Rational design of potent antagonists to the human growth hormone receptor. , 1992, Science.

[41]  J. Tschopp,et al.  The molecular architecture of the TNF superfamily. , 2002, Trends in biochemical sciences.

[42]  A. Hinck,et al.  Ternary Complex of Transforming Growth Factor-β1 Reveals Isoform-specific Ligand Recognition and Receptor Recruitment in the Superfamily* , 2010, The Journal of Biological Chemistry.

[43]  S. Skaper The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors. , 2008, CNS & neurological disorders drug targets.

[44]  T. Waldmann,et al.  Cooperative interactions between the interleukin 2 receptor alpha and beta chains alter the interleukin 2-binding affinity of the receptor subunits. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[45]  D. Harrison,et al.  The Jak/STAT pathway. , 2012, Cold Spring Harbor perspectives in biology.

[46]  J. Schlessinger,et al.  Demonstration of epidermal growth factor-induced receptor dimerization in living cells using a chemical covalent cross-linking agent. , 1988, The Journal of biological chemistry.

[47]  M. Bednarek,et al.  Mimicry of erythropoietin by a nonpeptide molecule. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Hong-Jian Zhu,et al.  A Pivotal Role for the Transmembrane Domain in Transforming Growth Factor-β Receptor Activation* , 1999, The Journal of Biological Chemistry.

[49]  B. Ursø,et al.  The insulin-like growth factor-I receptor. Structure, ligand-binding mechanism and signal transduction. , 1994, Hormone research.

[50]  T. Waldmann,et al.  Nanometer-scale organization of the alpha subunits of the receptors for IL2 and IL15 in human T lymphoma cells , 2008, Journal of Cell Science.

[51]  H. Rui,et al.  JAK2 activation and cell proliferation induced by antibody-mediated prolactin receptor dimerization. , 1994, Endocrinology.

[52]  David F. Burke,et al.  Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin , 2000, Nature.

[53]  A. Ullrich,et al.  Growth factor signaling by receptor tyrosine kinases , 1992, Neuron.

[54]  J. Darnell,et al.  The JAK-STAT pathway at twenty. , 2012, Immunity.

[55]  H. Lodish,et al.  The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif. , 2001, Molecular cell.

[56]  Kai Simons,et al.  Membrane organization and lipid rafts. , 2011, Cold Spring Harbor perspectives in biology.

[57]  Yoshua Bengio,et al.  Selective small molecule peptidomimetic ligands of TrkC and TrkA receptors afford discrete or complete neurotrophic activities. , 2005, Chemistry & biology.

[58]  Ronald W. Barrett,et al.  Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin , 1996, Science.

[59]  Edouard C. Nice,et al.  Ligand-induced Dimer-Tetramer Transition during the Activation of the Cell Surface Epidermal Growth Factor Receptor-A Multidimensional Microscopy Analysis* , 2005, Journal of Biological Chemistry.

[60]  Derek Toomre,et al.  Spatial control of EGF receptor activation by reversible dimerization on living cells , 2010, Nature.

[61]  A. Hinck,et al.  Assembly of TbetaRI:TbetaRII:TGFbeta ternary complex in vitro with receptor extracellular domains is cooperative and isoform-dependent. , 2005, Journal of molecular biology.

[62]  J. Massagué TGF‐β signaling in development and disease , 2012, FEBS letters.

[63]  A. D’Andrea,et al.  A constitutively activated chimeric cytokine receptor confers factor-independent growth in hematopoietic cell lines. , 1996, Blood.

[64]  D. Lauffenburger,et al.  Ligand/Receptor Signaling Threshold (LIST) Model Accounts for gp130‐Mediated Embryonic Stem Cell Self‐Renewal Responses to LIF and HIL‐6 , 2002, Stem cells.

[65]  M. Kawahara,et al.  Selection of highly productive mammalian cells based on an inducible growth advantage using an antibody/receptor chimera. , 2002, Journal of bioscience and bioengineering.

[66]  K. Fleming,et al.  Dimerization of the erythropoietin receptor transmembrane domain in micelles. , 2007, Journal of molecular biology.

[67]  H. Lodish,et al.  Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[68]  J. Tavernier,et al.  Functional analysis of leptin receptor activation using a Janus kinase/signal transducer and activator of transcription complementation assay. , 2004, Molecular Endocrinology.

[69]  B. Goldstein,et al.  Solution Assembly of a Soluble, Heteromeric, High Affinity Interleukin-2 Receptor Complex (*) , 1995, The Journal of Biological Chemistry.

[70]  K. Garcia,et al.  Shared cytokine signaling receptors: structural insights from the gp130 system. , 2004, Advances in protein chemistry.

[71]  S. Masuda,et al.  An extra high dose of erythropoietin fails to support the proliferation of erythropoietin dependent cell lines , 2011, Cytotechnology (Dordrecht).

[72]  K. Ferguson,et al.  Structure-based view of epidermal growth factor receptor regulation. , 2008, Annual review of biophysics.

[73]  Mart Saarma,et al.  The GDNF family: Signalling, biological functions and therapeutic value , 2002, Nature Reviews Neuroscience.

[74]  W. Vainchenker,et al.  An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. , 2006, Blood.

[75]  M. Auer,et al.  Beyond dimerization: a membrane-dependent activation model for interleukin-4 receptor-mediated signalling. , 2007, Journal of molecular biology.

[76]  P. Sathyanarayana,et al.  CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools. , 2009, Blood.

[77]  J. O’Shea,et al.  Janus kinases in immune cell signaling , 2009, Immunological reviews.

[78]  P. De Meyts,et al.  Receptor dimerization determines the effects of growth hormone in primary rat adipocytes and cultured human IM-9 lymphocytes. , 1994, Endocrinology.

[79]  R. Daly,et al.  Docking proteins , 2010, The FEBS journal.

[80]  Y. Yarden,et al.  The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[81]  John Kuriyan,et al.  An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor , 2006, Cell.

[82]  Masashi Suzuki,et al.  Sulfated Glycosaminoglycans Are Required for Specific and Sensitive Fibroblast Growth Factor (FGF) 19 Signaling via FGF Receptor 4 and betaKlotho* , 2011, The Journal of Biological Chemistry.

[83]  S. Sprang,et al.  Seeing double: Crystal structures of the type I TNF receptor , 1996, Journal of molecular recognition : JMR.

[84]  M. Wada,et al.  The 20-kilodalton (kDa) human growth hormone (hGH) differs from the 22-kDa hGH in the effect on the human prolactin receptor. , 1999, Endocrinology.

[85]  Hitoshi Sakuraba,et al.  ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth , 2004, Journal of Cell Science.

[86]  M. Kawahara,et al.  T cell growth control using hapten-specific antibody/interleukin-2 receptor chimera. , 2009, Cytokine.

[87]  Huan-Xiang Zhou,et al.  A Common Model for Cytokine Receptor Activation: Combined Scissor-Like Rotation and Self-Rotation of Receptor Dimer Induced by Class I Cytokine , 2012, PLoS Comput. Biol..

[88]  R. Zivin,et al.  Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity. , 1997, Chemistry & biology.

[89]  Peter Klein,et al.  A structure-based model for ligand binding and dimerization of EGF receptors. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[90]  M. Bilgen,et al.  Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. , 2010, The Journal of clinical investigation.

[91]  Yen-Ming Hsu,et al.  Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. , 2005, Biochemistry.

[92]  A. Hinck,et al.  Assembly of TβRI: TβRII:TGFβ ternary complex in vitro with receptor extracellular domains is cooperative and isoform-dependent , 2005 .

[93]  Diego Jaitin,et al.  Inquiring into the Differential Action of Interferons (IFNs): an IFN-α2 Mutant with Enhanced Affinity to IFNAR1 Is Functionally Similar to IFN-β , 2006, Molecular and Cellular Biology.

[94]  R. Germain,et al.  T-cell signaling: The importance of receptor clustering , 1997, Current Biology.

[95]  N. Udagawa,et al.  Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[96]  Michael Loran Dustin,et al.  Analysis of two-dimensional dissociation constant of laterally mobile cell adhesion molecules. , 2007, Biophysical journal.

[97]  K. Ballmer-Hofer,et al.  Transmembrane domain‐mediated orientation of receptor monomers in active VEGFR‐2 dimers , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[98]  M. Ballmaier,et al.  Grafting of thrombopoietin‐mimetic peptides into cystine knot miniproteins yields high‐affinity thrombopoietin antagonists and agonists , 2006, The FEBS journal.

[99]  L. Pike,et al.  The Intracellular Juxtamembrane Domain of the Epidermal Growth Factor (EGF) Receptor Is Responsible for the Allosteric Regulation of EGF Binding*♦ , 2009, Journal of Biological Chemistry.

[100]  J. Scheller,et al.  gp130 dimerization in the absence of ligand: preformed cytokine receptor complexes. , 2006, Biochemical and biophysical research communications.

[101]  T. Malek,et al.  Interleukin-2 receptor signaling: at the interface between tolerance and immunity. , 2010, Immunity.

[102]  H. Lodish,et al.  Homodimerization and constitutive activation of the erythropoietin receptor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[103]  J. Beechem,et al.  Preparation and characterization of Alexa Fluor 594-labeled epidermal growth factor for fluorescence resonance energy transfer studies: application to the epidermal growth factor receptor. , 2004, Analytical biochemistry.

[104]  L. Barbeito,et al.  Modulation of p75NTR‐dependent motor neuron death by a small non‐peptidyl mimetic of the neurotrophin loop 1 domain , 2006, The European journal of neuroscience.

[105]  M. Kawahara,et al.  Growth control of genetically modified cells using an antibody/c-Kit chimera. , 2012, Journal of bioscience and bioengineering.

[106]  Junxia Xie,et al.  PREASSEMBLY AND LIGAND-INDUCED CHANGES OF THE INTERFERON RECEPTOR COMPLEX IN CELLS* , 2002 .

[107]  E. Wolf,et al.  The epidermal growth factor receptor ligands at a glance , 2009, Journal of cellular physiology.

[108]  Wei Cheng,et al.  Characterization of a soluble ternary complex formed between human interferon‐β‐1a and its receptor chains , 1999, Protein science : a publication of the Protein Society.

[109]  K. Christopher Garcia,et al.  Molecular and Structural Basis of Cytokine Receptor Pleiotropy in the Interleukin-4/13 System , 2008, Cell.

[110]  K. Garcia,et al.  Hexameric Structure and Assembly of the Interleukin-6/IL-6 α-Receptor/gp130 Complex , 2003, Science.

[111]  J K Frederiksen,et al.  Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. , 2000, Science.

[112]  A Whitty,et al.  Small molecule cytokine mimetics. , 1999, Chemistry & biology.

[113]  K. Norga,et al.  Receptors that induce erythroid differentiation of Ba/F3 cells: structural requirements and effect on STAT5 binding. , 1997, Blood.

[114]  T. Walz,et al.  Ligand binding induces a conformational change in ifnar1 that is propagated to its membrane-proximal domain. , 2008, Journal of molecular biology.

[115]  M. Kawahara,et al.  Growth promotion of genetically modified hematopoietic progenitors using an antibody/c-Mpl chimera. , 2011, Cytokine.

[116]  M. Gavutis,et al.  Differential receptor subunit affinities of type I interferons govern differential signal activation. , 2007, Journal of molecular biology.

[117]  S. Sharpe,et al.  Interaction between ErbB‐1 and ErbB‐2 transmembrane domains in bilayer membranes , 2002, FEBS letters.

[118]  G. Blumenschein Insulin-like growth factor receptor. , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[119]  Michael W Parker,et al.  Model for growth hormone receptor activation based on subunit rotation within a receptor dimer , 2005, Nature Structural &Molecular Biology.

[120]  Diego Jaitin,et al.  The Stability of the Ternary Interferon-Receptor Complex Rather than the Affinity to the Individual Subunits Dictates Differential Biological Activities* , 2008, Journal of Biological Chemistry.

[121]  L. Alberghina,et al.  A New Nerve Growth Factor-Mimetic Peptide Active on Neuropathic Pain in Rats , 2008, The Journal of Neuroscience.

[122]  Robert M. Stroud,et al.  Efficiency of signalling through cytokine receptors depends critically on receptor orientation , 1998, Nature.

[123]  D. Nikolov,et al.  Cell-cell signaling via Eph receptors and ephrins. , 2007, Current opinion in cell biology.

[124]  J. Baselga,et al.  Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 , 2009, Nature Reviews Cancer.

[125]  Adrian Whitty,et al.  Cooperativity and biological complexity. , 2008, Nature chemical biology.

[126]  M. Boyle,et al.  Homodimerization of erythropoietin receptor by a bivalent monoclonal antibody triggers cell proliferation and differentiation of erythroid precursors. , 1997, Blood.

[127]  Xiangling Xiong,et al.  Nanoparticle-mediated IgE-receptor aggregation and signaling in RBL mast cells. , 2009, Journal of the American Chemical Society.

[128]  Y Ikeda,et al.  A non‐peptide compound which can mimic the effect of thrombopoietin via c‐Mpl , 1998, FEBS letters.

[129]  O. Bocharova,et al.  Spatial structure of the transmembrane domain heterodimer of ErbB1 and ErbB2 receptor tyrosine kinases. , 2010, Journal of molecular biology.

[130]  D. Aunis,et al.  Transmembrane peptides as inhibitors of ErbB receptor signaling. , 2004, Molecular biology of the cell.

[131]  D. Baccanari,et al.  Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. , 1997, Science.

[132]  C. D. Krause,et al.  Interferons, interferon‐like cytokines, and their receptors , 2004, Immunological reviews.

[133]  A. Arseniev,et al.  Transmembrane domain of EphA1 receptor forms dimers in membrane-like environment. , 2008, Biochimica et biophysica acta.

[134]  H. Miyazaki,et al.  Switching constant domains enhances agonist activities of antibodies to a thrombopoietin receptor , 2008, Nature Biotechnology.

[135]  J. Bussel,et al.  Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study , 2011, The Lancet.

[136]  T M Jovin,et al.  Oligomerization of epidermal growth factor receptors on A431 cells studied by time-resolved fluorescence imaging microscopy. A stereochemical model for tyrosine kinase receptor activation , 1995, The Journal of cell biology.

[137]  D A Lauffenburger,et al.  Analysis of Mammalian Cell Growth Factor Receptor Dynamics a , 1987, Annals of the New York Academy of Sciences.

[138]  M. Saarma,et al.  GDNF Family Neurotrophic Factor Signaling: Four Masters, One Servant? , 1999, Molecular and Cellular Neuroscience.

[139]  D. Banner,et al.  Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: Implications for TNF receptor activation , 1993, Cell.

[140]  Joanne Oates,et al.  Strong oligomerization behavior of PDGFbeta receptor transmembrane domain and its regulation by the juxtamembrane regions. , 2010, Biochimica et biophysica acta.

[141]  S. Constantinescu,et al.  Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. , 2003, Molecular cell.

[142]  T. Jovin,et al.  Distribution of resting and ligand-bound ErbB1 and ErbB2 receptor tyrosine kinases in living cells using number and brightness analysis , 2010, Proceedings of the National Academy of Sciences.

[143]  Ursula Klingmüller,et al.  Self assembly of the transmembrane domain promotes signal transduction through the erythropoietin receptor , 2001, Current Biology.

[144]  I. Chaiken,et al.  Interleukin-5 Receptor Subunit Oligomerization and Rearrangement Revealed by Fluorescence Resonance Energy Transfer Imaging* , 2008, Journal of Biological Chemistry.

[145]  Angel F. Lopez,et al.  Molecular assembly of the ternary granulocyte-macrophage colony-stimulating factor receptor complex. , 2003, Blood.

[146]  M. Ballinger,et al.  Will any dimer do? , 1998, Nature Structural Biology.

[147]  Alan E Mark,et al.  Turning the growth hormone receptor on: Evidence that hormone binding induces subunit rotation , 2010, Proteins.

[148]  G. Yancopoulos,et al.  The alphas, betas, and kinases of cytokine receptor complexes , 1993, Cell.

[149]  C. Heldin,et al.  Specificity, diversity, and regulation in TGF‐β superfamily signaling , 1999 .

[150]  A. Buj-Bello,et al.  Characterization of a multicomponent receptor for GDNF , 1996, Nature.

[151]  Mark A. Hall,et al.  Interleukin-11 Signals through the Formation of a Hexameric Receptor Complex* , 2000, The Journal of Biological Chemistry.

[152]  A. Bader,et al.  Ligand-induced EGF Receptor Oligomerization Is Kinase-dependent and Enhances Internalization* , 2010, The Journal of Biological Chemistry.

[153]  P. W. Janes,et al.  Architecture of Eph receptor clusters , 2010, Proceedings of the National Academy of Sciences.

[154]  I. Jang,et al.  Grb2, a simple adapter with complex roles in lymphocyte development, function, and signaling , 2009, Immunological reviews.

[155]  Wei Liu,et al.  Functional impact of manipulation on the relative orientation of human prolactin receptor domains. , 2011, Biochemistry.

[156]  T. Arakawa,et al.  Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: one high-affinity and one low-affinity interaction. , 1996, Biochemistry.

[157]  K. Clauser,et al.  Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. , 1991, Science.

[158]  P. Pilch,et al.  Mechanism of epidermal growth factor receptor autophosphorylation and high-affinity binding. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[159]  I. Ishida,et al.  Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2 , 2004, Cell Death and Differentiation.

[160]  M. Waters,et al.  Activation of Chimeric and Full-length Growth Hormone Receptors by Growth Hormone Receptor Monoclonal Antibodies , 1998, The Journal of Biological Chemistry.

[161]  H. Loetscher,et al.  Binding and regulation of cellular functions by monoclonal antibodies against human tumor necrosis factor receptors , 1990, The Journal of experimental medicine.

[162]  Michael Loran Dustin,et al.  Low Affinity Interaction of Human or Rat T Cell Adhesion Molecule CD2 with Its Ligand Aligns Adhering Membranes to Achieve High Physiological Affinity* , 1997, The Journal of Biological Chemistry.

[163]  Peter Klein,et al.  On the nature of low- and high-affinity EGF receptors on living cells. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[164]  R. Adar,et al.  Differential Activation of Cysteine‐Substitution Mutants of Fibroblast Growth Factor Receptor 3 Is Determined by Cysteine Localization , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[165]  L. Willen,et al.  Molecular and Therapeutic Characterization of Anti-ectodysplasin A Receptor (EDAR) Agonist Monoclonal Antibodies* , 2011, The Journal of Biological Chemistry.

[166]  L S Mulcahy,et al.  Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1. , 1998, Biochemistry.

[167]  Patrick England,et al.  Structural characterization of the stem-stem dimerization interface between prolactin receptor chains complexed with the natural hormone. , 2010, Journal of molecular biology.

[168]  Jae-Hoon Kim,et al.  Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains , 2002, Cell.

[169]  K. Burgess,et al.  Long-Lasting Rescue of Age-Associated Deficits in Cognition and the CNS Cholinergic Phenotype by a Partial Agonist Peptidomimetic Ligand of TrkA , 2004, The Journal of Neuroscience.

[170]  I. Wilson,et al.  Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. , 1999, Science.

[171]  H. Lodish,et al.  Activation and inhibition of erythropoietin receptor function: role of receptor dimerization , 1994, Molecular and cellular biology.

[172]  M. Lemmon,et al.  The Single Transmembrane Domains of ErbB Receptors Self-associate in Cell Membranes* , 2002, The Journal of Biological Chemistry.

[173]  I. Wilson,et al.  The structure, organization, activation and plasticity of the erythropoietin receptor. , 1999, Current opinion in structural biology.

[174]  Pascal Schneider,et al.  Two Adjacent Trimeric Fas Ligands Are Required for Fas Signaling and Formation of a Death-Inducing Signaling Complex , 2003, Molecular and Cellular Biology.

[175]  R. Harris,et al.  Autocrine, paracrine and juxtacrine signaling by EGFR ligands. , 2005, Cellular signalling.

[176]  E. Elson,et al.  Oligomerization of the EGF receptor investigated by live cell fluorescence intensity distribution analysis. , 2007, Biophysical journal.

[177]  S R Sprang,et al.  Structures of the extracellular domain of the type I tumor necrosis factor receptor. , 1996, Structure.

[178]  Y. Yarden,et al.  Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. , 1987, Biochemistry.

[179]  A. Whitty,et al.  Interaction affinity between cytokine receptor components on the cell surface. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[180]  Y. Maeda,et al.  Structural remodeling, trafficking and functions of glycosylphosphatidylinositol-anchored proteins. , 2011, Progress in lipid research.

[181]  R. Lier,et al.  Common γ chain cytokines: Dissidence in the details , 2007 .

[182]  H. Lodish,et al.  Active Conformation of the Erythropoietin Receptor , 2006, Journal of Biological Chemistry.

[183]  A. Yoshimura,et al.  Ligand-induced activation of chimeric receptors between the erythropoietin receptor and receptor tyrosine kinases. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[184]  I. Wilson,et al.  Erythropoietin receptor activation by a ligand-induced conformation change. , 1999, Science.

[185]  Jacob Piehler,et al.  Determination of the two-dimensional interaction rate constants of a cytokine receptor complex. , 2006, Biophysical journal.

[186]  Enrico A. Stura,et al.  Functional Mimicry of a Protein Hormone by a Peptide Agonist: The EPO Receptor Complex at 2.8 Å , 1996, Science.

[187]  E. Whitehorn,et al.  A potent dimeric peptide antagonist of interleukin-5 that binds two interleukin-5 receptor alpha chains. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[188]  Peter O. Krutzik,et al.  Structural Linkage between Ligand Discrimination and Receptor Activation by Type I Interferons , 2011, Cell.

[189]  C. Peng,et al.  Activin receptor-like kinases: structure, function and clinical implications. , 2006, Endocrine, metabolic & immune disorders drug targets.

[190]  A. C. Rigby,et al.  Oligomerization of the EGF receptor transmembrane domain: a 2H NMR study in lipid bilayers. , 1997, Biochemistry.

[191]  D. Blumenthal,et al.  PDGF‐induced proliferation in human arterial and venous smooth muscle cells: Molecular basis for differential effects of PDGF isoforms , 2011, Journal of cellular biochemistry.

[192]  A. Whitty,et al.  New ways to target old receptors. , 2008, Current opinion in chemical biology.

[193]  J. Torres,et al.  The strong dimerization of the transmembrane domain of the fibroblast growth factor receptor (FGFR) is modulated by C‐terminal juxtamembrane residues , 2009, Protein science : a publication of the Protein Society.

[194]  M. Brizzi,et al.  Prolactin increases the susceptibility of primary leukemia cells to NK and LAK effectors. , 1996, Advances in neuroimmunology.

[195]  C. Heldin,et al.  Ligand-induced dimerization of growth factor receptors: variations on the theme. , 1996, Cytokine & growth factor reviews.

[196]  Holger Conzelmann,et al.  Rapid phospho-turnover by receptor tyrosine kinases impacts downstream signaling and drug binding. , 2011, Molecular cell.

[197]  Gideon Schreiber,et al.  Stochastic Receptor Expression Determines Cell Fate upon Interferon Treatment , 2011, Molecular and Cellular Biology.

[198]  M. Lemmon,et al.  Structural Basis for Negative Cooperativity in Growth Factor Binding to an EGF Receptor , 2010, Cell.

[199]  P. Comoglio,et al.  Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. , 1998, Journal of cell science.

[200]  S. Harper,et al.  Trk Neurotrophin Receptor Activators. , 2002, Drug news & perspectives.

[201]  Yang Liu,et al.  A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone , 2010, Proceedings of the National Academy of Sciences.

[202]  S. Lata,et al.  Lateral ligand-receptor interactions on membranes probed by simultaneous fluorescence-interference detection. , 2005, Biophysical journal.

[203]  B. Klein,et al.  An agonist anti-human CD40 monoclonal antibody that induces dendritic cell formation and maturation and inhibits proliferation of a myeloma cell line. , 1999, Hybridoma.

[204]  S. Lata,et al.  Ligand-induced assembling of the type I interferon receptor on supported lipid bilayers. , 2004, Journal of molecular biology.

[205]  D. Boger,et al.  Cytokine receptor dimerization and activation: prospects for small molecule agonists. , 2001, Bioorganic & medicinal chemistry.

[206]  M. Kawahara,et al.  Mimicry of erythropoietin and interleukin-6 signalling by an antibody/cytokine receptor chimera in murine myeloid 32D cells. , 2007, Journal of biochemistry.

[207]  R M Siegel,et al.  A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. , 2000, Science.

[208]  P. Knaus,et al.  Recent advances in BMP receptor signaling. , 2009, Cytokine & growth factor reviews.

[209]  Roman G. Efremov,et al.  Spatial Structure of the Dimeric Transmembrane Domain of the Growth Factor Receptor ErbB2 Presumably Corresponding to the Receptor Active State* , 2008, Journal of Biological Chemistry.

[210]  R. Quirion,et al.  Potent human p140-TrkA agonists derived from an anti-receptor monoclonal antibody , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[211]  W. Sebald,et al.  Conversion of human interleukin‐4 into a high affinity antagonist by a single amino acid replacement. , 1992, The EMBO journal.

[212]  S. Watowich Activation of erythropoietin signaling by receptor dimerization. , 1999, The international journal of biochemistry & cell biology.

[213]  D. Lauffenburger,et al.  Interleukin 2 (IL-2) variants engineered for increased IL-2 receptor α-subunit affinity exhibit increased potency arising from a cell surface ligand reservoir effect , 2004 .

[214]  Ian A Wilson,et al.  Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[215]  L. Cantley,et al.  Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[216]  R. D'Andrea,et al.  Molecular basis of cytokine receptor activation , 2010, IUBMB life.

[217]  L. Mátyus,et al.  Non-random distribution of interleukin receptors on the cell surface. , 2009, Chemphyschem : a European journal of chemical physics and physical chemistry.

[218]  Miho Suzuki,et al.  IL-6/IL-6 receptor system and its role in physiological and pathological conditions. , 2012, Clinical science.

[219]  D. Christiansen,et al.  Inducible Dimerization of RET Reveals a Specific AKT Deregulation in Oncogenic Signaling* , 2005, Journal of Biological Chemistry.

[220]  G. Forte,et al.  Agonist monoclonal antibodies against HGF receptor protect cardiac muscle cells from apoptosis. , 2010, American journal of physiology. Heart and circulatory physiology.

[221]  T. Honjo,et al.  Why are multiple chains required for the interleukin 2 receptor? , 1990, Progress in growth factor research.